Desirability：必要性、Viability：持続可能性、Feasibility：実現可能性
サイバーフィジカル分野におけるイノベーションのアイデアを思い付いた場合、次のステップはどうすればよいのでしょうか？誰もが何から取り組むのか理解していたり、成功する自信があるわけではありません。当社では、DVF(Desirability：必要性、Viability：持続可能性、Feasibility：実現可能性) で知られるデザイン思考の手法を採用し、製品開発を進めています。
What next for precision medicine?
The world of DNA testing is changing fast and the race is on to provide cheap, quick genetic diagnoses for patients. Symon Cotton, Head of Life Sciences takes a look at the opportunities on offer for companies working in this dynamic field.
ファーマの未来はコラボレーションにある
Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.
Start-up technology risk management in The Engine venture ecosystem
Founders of early-stage start-ups are passionate, driven and optimistic. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong.
Champions of Cell and Gene Therapy – The Medicine Maker
How do we ensure that not only the rich benefit from cell and gene therapy? Rob Collison of Cambridge Consultants says: It’s about more than cutting costs
Digital biomarkers for patient-empowering connected health
The future promises a digitally connected healthcare system that empowers both patients and carers alike. So, what’s the next step for pharma companies and device developers with ambitions in the space?